REGENX wins FDA orphan designation for familial hypercholesterolemia therapy
The REGENX program consists of a NAV rAAV8 vector expressing a normal copy of the human low-density lipoprotein receptor (hLDLR) gene. The study, conducted at University of Pennsylvania
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.